Literature DB >> 29476020

Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription.

Yu-Fang Huang1, Yi-Hui Wu1, Wen-Fang Cheng2, Shu-Ling Peng3, Wan-Lin Shen4, Cheng-Yang Chou5.   

Abstract

Purpose: Malignant ascites of epithelial ovarian cancer (EOC) helps identify prognostic biomarkers or mechanisms of tumor progression. Vitamin D-binding protein (DBP) was revealed to be upregulated in EOC ascites in our previous proteomic study. Here, we examined the role of DBP in EOC.Experimental Design: We analyzed ascites, serum, and tissue samples of patients with newly diagnosed EOC to determine the prognostic effects of DBP. We verified DBP function using orthotopic animal models and DBP regulation in ovarian cancer cell lines.
Results: Elevated ascitic DBP was significantly associated with poor response to chemotherapy, short progression-free interval, increased cancer progression, and death. Ascitic DBP overexpression was an independent unfavorable biomarker for progression-free survival; DBP overexpression in cancerous tissue was significantly related to chemoresistance. In vivo and in vitro investigations demonstrated an important role for DBP in ovarian cancer progression. Orthotopic model mice inoculated with DBP knockdown ovarian cancer cells displayed a significant reduction in tumor formation, malignant cell number, ascitic DBP levels, invasiveness, and metastasis, and increased survival compared with controls. In presence of vitamin D receptor (VDR), DBP promoted cell aggression (invasion and doubling time) via activation of the insulin-like growth factor-1/insulin-like growth factor-binding protein-2/Akt axis, and induced suppression of vitamin D-responsive genes. A NF-κB p65-binding site in the VDR promoter was identified as a major determinant of DBP-dependent VDR promoter activation.Conclusions: This study highlights the importance of DBP in ovarian tumor progression and the potential application of DBP as a therapeutic target for EOC. Clin Cancer Res; 24(13); 3217-28. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29476020     DOI: 10.1158/1078-0432.CCR-17-2943

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data.

Authors:  Lazaro Hiram Betancourt; Krzysztof Pawłowski; Jonatan Eriksson; A Marcell Szasz; Shamik Mitra; Indira Pla; Charlotte Welinder; Henrik Ekedahl; Per Broberg; Roger Appelqvist; Maria Yakovleva; Yutaka Sugihara; Kenichi Miharada; Christian Ingvar; Lotta Lundgren; Bo Baldetorp; Håkan Olsson; Melinda Rezeli; Elisabet Wieslander; Peter Horvatovich; Johan Malm; Göran Jönsson; György Marko-Varga
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

Review 2.  Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms.

Authors:  Andraž Dovnik; Nina Fokter Dovnik
Journal:  Cells       Date:  2020-02-01       Impact factor: 6.600

3.  Gene networks and transcriptional regulators associated with liver cancer development and progression.

Authors:  Tatiana Meier; Max Timm; Matteo Montani; Ludwig Wilkens
Journal:  BMC Med Genomics       Date:  2021-02-04       Impact factor: 3.063

4.  Differential Expression Profiles and Function Prediction of Transfer RNA-Derived Fragments in High-Grade Serous Ovarian Cancer.

Authors:  Buze Chen; Sicong Liu; Haihong Wang; Guilin Li; Xiaoyuan Lu; Hao Xu
Journal:  Biomed Res Int       Date:  2021-03-30       Impact factor: 3.411

5.  Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the STAT3 pathway.

Authors:  Li Yang; Zenghuan Tan; Yukun Li; Xueqiang Zhang; Yiping Wu; Baoyuan Xu; Mei Wang
Journal:  J Clin Lab Anal       Date:  2020-08-26       Impact factor: 3.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.